270 related articles for article (PubMed ID: 25944485)
1. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
[TBL] [Abstract][Full Text] [Related]
2. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
3. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
6. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
8. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Lee A; Djamgoz MBA
Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
[TBL] [Abstract][Full Text] [Related]
12. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
[TBL] [Abstract][Full Text] [Related]
13. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor in triple negative breast cancer.
McNamara KM; Yoda T; Takagi K; Miki Y; Suzuki T; Sasano H
J Steroid Biochem Mol Biol; 2013 Jan; 133():66-76. PubMed ID: 22982153
[TBL] [Abstract][Full Text] [Related]
15. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
16. Androgen blockade based clinical trials landscape in triple negative breast cancer.
Shi Y; Yang F; Huang D; Guan X
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):283-290. PubMed ID: 29807045
[TBL] [Abstract][Full Text] [Related]
17. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
18. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Grellety T
Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
[TBL] [Abstract][Full Text] [Related]
19. [Research Progress in Androgen Receptor and Triple Negative Breast Cancer].
Jia MY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):303-310. PubMed ID: 37157080
[TBL] [Abstract][Full Text] [Related]
20. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
Asano Y; Kashiwagi S; Onoda N; Kurata K; Morisaki T; Noda S; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Br J Cancer; 2016 Jan; 114(1):14-20. PubMed ID: 26757422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
